Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Uterine Neoplasms 1Urologic Neoplasms 1Kidney Neoplasms 1Kidney Diseases 1Endometrial Neoplasms 1Carcinoma, Renal Cell 1Carcinoma 1

Interventions

Gemcitabine 9pembrolizumab 7Cisplatin 5enfortumab vedotin 4atezolizumab 4Trastuzumab 4Carboplatin 4Sunitinib 3Pemetrexed 3Mitomycin 3cabozantinib 2Water 2Sugammadex 2Standard of Care 2Saline Solution 2Paclitaxel 2Nivolumab 2Neostigmine 2Docetaxel 2Cetuximab 2Bevacizumab 2zidovudine 5'-monophosphate-mannose-albumin conjugate 1vinflunine 1valrubicin 1tucatinib 1tislelizumab 1testosterone 17 beta-cypionate 1temsirolimus 1relatlimab 1poly ICLC 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Urologic Neoplasms × VMBP protocol × Clear all
NCT04300140 2023-10-30

Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma

Aravive, Inc.

Phase 1/2 Terminated
72 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡